Methods for determining cost-benefit ratios for pharmaceuticals in Germany

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Autoren

  • J. Matthias Graf V. D. Schulenburg
  • Christoph Vauth
  • Thomas Mittendorf
  • Wolfgang Greiner

Externe Organisationen

  • Universität Bielefeld
Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
Seiten (von - bis)S5-S31
FachzeitschriftEuropean Journal of Health Economics
Jahrgang8
AusgabenummerSupplement 1
Frühes Online-Datum21 Juni 2007
PublikationsstatusVeröffentlicht - Sept. 2007

Abstract

The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

Methods for determining cost-benefit ratios for pharmaceuticals in Germany. / Graf V. D. Schulenburg, J. Matthias; Vauth, Christoph; Mittendorf, Thomas et al.
in: European Journal of Health Economics, Jahrgang 8, Nr. Supplement 1, 09.2007, S. S5-S31.

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Graf V. D. Schulenburg, JM, Vauth, C, Mittendorf, T & Greiner, W 2007, 'Methods for determining cost-benefit ratios for pharmaceuticals in Germany', European Journal of Health Economics, Jg. 8, Nr. Supplement 1, S. S5-S31. https://doi.org/10.1007/s10198-007-0063-4
Graf V. D. Schulenburg, J. M., Vauth, C., Mittendorf, T., & Greiner, W. (2007). Methods for determining cost-benefit ratios for pharmaceuticals in Germany. European Journal of Health Economics, 8(Supplement 1), S5-S31. https://doi.org/10.1007/s10198-007-0063-4
Graf V. D. Schulenburg JM, Vauth C, Mittendorf T, Greiner W. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. European Journal of Health Economics. 2007 Sep;8(Supplement 1):S5-S31. Epub 2007 Jun 21. doi: 10.1007/s10198-007-0063-4
Graf V. D. Schulenburg, J. Matthias ; Vauth, Christoph ; Mittendorf, Thomas et al. / Methods for determining cost-benefit ratios for pharmaceuticals in Germany. in: European Journal of Health Economics. 2007 ; Jahrgang 8, Nr. Supplement 1. S. S5-S31.
Download
@article{10d287fe9f1349ee9b99527f5a36f768,
title = "Methods for determining cost-benefit ratios for pharmaceuticals in Germany",
abstract = "The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.",
author = "{Graf V. D. Schulenburg}, {J. Matthias} and Christoph Vauth and Thomas Mittendorf and Wolfgang Greiner",
year = "2007",
month = sep,
doi = "10.1007/s10198-007-0063-4",
language = "English",
volume = "8",
pages = "S5--S31",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",
number = "Supplement 1",

}

Download

TY - JOUR

T1 - Methods for determining cost-benefit ratios for pharmaceuticals in Germany

AU - Graf V. D. Schulenburg, J. Matthias

AU - Vauth, Christoph

AU - Mittendorf, Thomas

AU - Greiner, Wolfgang

PY - 2007/9

Y1 - 2007/9

N2 - The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.

AB - The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.

UR - http://www.scopus.com/inward/record.url?scp=34548012137&partnerID=8YFLogxK

U2 - 10.1007/s10198-007-0063-4

DO - 10.1007/s10198-007-0063-4

M3 - Article

C2 - 17582539

AN - SCOPUS:34548012137

VL - 8

SP - S5-S31

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - Supplement 1

ER -